Cytosorbents Corp Sample Contracts

CYTOSORBENTS CORPORATION UNDERWRITING AGREEMENT
Underwriting Agreement • January 14th, 2015 • Cytosorbents Corp • Surgical & medical instruments & apparatus • New York
AutoNDA by SimpleDocs
COMMON STOCK PURCHASE WARRANT CYTOSORBENTS CORPORATION
Cytosorbents Corp • December 11th, 2023 • Surgical & medical instruments & apparatus

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December 12, 2023 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on December 12, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from CytoSorbents Corporation, a Delaware corporation (the “Company”), up to _____ shares of common stock, par value $0.001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • December 9th, 2011 • Cytosorbents Corp • Surgical & medical instruments & apparatus • Nevada

REGISTRATION RIGHTS AGREEMENT (this "Agreement"), dated as of December 8, 2011, by and between CYTOSORBENTS CORPORATION, a Nevada corporation, (the "Company"), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with it permitted assigns, the “Buyer”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the "Purchase Agreement").

SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • February 13th, 2014 • Cytosorbents Corp • Surgical & medical instruments & apparatus

This Securities Purchase Agreement (this “Agreement”) is dated as of February [ ], 2014, between Cytosorbents Corporation, a Nevada corporation (the “Company”) and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

CytoSorbents Corporation Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement
Cytosorbents Corp • November 5th, 2015 • Surgical & medical instruments & apparatus • New York

CytoSorbents Corporation, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:

5,263,158 Shares CYTOSORBENTS CORPORATION Common Stock UNDERWRITING AGREEMENT
Underwriting Agreement • July 22nd, 2020 • Cytosorbents Corp • Surgical & medical instruments & apparatus • New York
COMMON STOCK PURCHASE WARRANT CYTOSORBENTS CORPORATION
Cytosorbents Corp • February 14th, 2014 • Surgical & medical instruments & apparatus

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Cytosorbents Corporation., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

COMMON STOCK PURCHASE WARRANT CYTOSORBENTS CORPORATION
Cytosorbents Corp • March 12th, 2014 • Surgical & medical instruments & apparatus

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Brean Capital, LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after February 14, 1014, the effective date of Registration Statement No. 333-193053 (the “Initial Exercise Date”) and on or prior to the close of business on the five (5) year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Cytosorbents Corporation., a Nevada corporation (the “Company”), up to 1,224,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Contract
Gilder Enterprises Inc • July 6th, 2006 • Services-computer programming, data processing, etc. • New York

THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SAID ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO GILDER ENTERPRISES, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

SUBSCRIPTION AGREEMENT
Subscription Agreement • July 1st, 2008 • MedaSorb Technologies CORP • Surgical & medical instruments & apparatus • New York

THIS SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of June __, 2008, by and among MedaSorb Technologies Corporation, a Nevada corporation (the “Company”), and the subscribers identified on the signature page hereto (each a “Subscriber” and collectively “Subscribers”).

OPEN MARKET SALE AGREEMENTSM
Open Market Sale • July 9th, 2019 • Cytosorbents Corp • Surgical & medical instruments & apparatus • New York
AGREEMENT AND PLAN OF MERGER by and among GILDER ENTERPRISES, INC., MEDASORB ACQUISITION, INC. and MEDASORB CORPORATION June 29, 2006
Agreement and Plan of Merger • December 13th, 2006 • MedaSorb Technologies CORP • Surgical & medical instruments & apparatus • Delaware

THIS AGREEMENT AND PLAN OF MERGER is entered into as of June 29, 2006 by and among GILDER ENTERPRISES, INC. a Nevada corporation (“Parent”), MEDASORB ACQUISITION, INC., a Delaware corporation and a wholly-owned subsidiary of Parent (“Acquisition Corp.”), and MEDASORB CORPORATION., a Delaware corporation (the “Company”).

RECITALS
Employment Agreement • December 13th, 2006 • MedaSorb Technologies CORP • Surgical & medical instruments & apparatus • New York
EMPLOYMENT AGREEMENT
Employment Agreement • January 7th, 2014 • Cytosorbents Corp • Surgical & medical instruments & apparatus • New Jersey

THIS EMPLOYMENT AGREEMENT (this “Agreement”) is entered into on December 31, 2013, by and between CytoSorbents Corporation and its wholly-owned subsidiary CytoSorbents, Inc. (collectively the “Company”), and Phillip P. Chan (“Employee”).

PURCHASE AGREEMENT
Purchase Agreement • December 9th, 2011 • Cytosorbents Corp • Surgical & medical instruments & apparatus • Nevada

PURCHASE AGREEMENT (the “Agreement”), dated as of December 8, 2011, by and between CYTOSORBENTS CORPORATION, a Nevada corporation, (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).

CYTOSORBENTS CORPORATION PLACEMENT AGENCY AGREEMENT
Placement Agency Agreement • March 12th, 2014 • Cytosorbents Corp • Surgical & medical instruments & apparatus • New York
Executive Employment Agreement
Executive Employment Agreement • September 19th, 2023 • Cytosorbents Corp • Surgical & medical instruments & apparatus • New Jersey

This Executive Employment Agreement (the “Employment Agreement” or “Agreement”) is made and entered by and between Kathleen P. Bloch (the “Executive”), and CytoSorbents Medical, Inc., on behalf of itself, its parent CytoSorbents Corporation, and all other affiliates and subsidiaries thereof (collectively, the “Company”), dated as of September 18, 2023.

PURCHASE AGREEMENT
Purchase Agreement • May 10th, 2010 • Cytosorbents Corp • Surgical & medical instruments & apparatus • Nevada

PURCHASE AGREEMENT (the “Agreement”), dated as of May 5, 2010, by and between MEDASORB TECHNOLOGIES CORPORATION, a Nevada corporation, (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).

Restricted Stock Agreement under the CytoSorbents Corporation 2014 Long-Term Incentive Plan Grantee: ________________ No. of Shares: ___________
Restricted Stock Agreement • April 6th, 2015 • Cytosorbents Corp • Surgical & medical instruments & apparatus • Delaware

This Agreement (the “Agreement”) evidences the award of ____________ restricted shares (each, an “Award Share,” and collectively, the “Award Shares”) of the Common Stock of CytoSorbents Corporation, a Delaware corporation (the “Company”), granted to you, _______________________, effective as of ____________ (the “Grant Date”), pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the “Plan”) and conditioned upon your agreement to the terms described below. All of the provisions of the Plan are expressly incorporated into this Agreement.

CytoSorbents Corporation, A DELAWARE CORPORATION CytoSorbEnts Medical, Inc., a delaware corporation WESTERN ALLIANCE BANK, an arizona corporation AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT
Loan and Security Agreement • April 4th, 2018 • Cytosorbents Corp • Surgical & medical instruments & apparatus • California

This Amended and Restated Loan And Security Agreement (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) is entered into as of March 29, 2018, by and between Western Alliance Bank, an Arizona corporation (“Bank”), and CytoSorbents Corporation, a Delaware corporation and CytoSorbents Medical, Inc., a Delaware corporation (individually and collectively, jointly and severally “Borrower”) and amends and restates in its entirety that certain Loan and Security Agreement dated as of June 30, 2016 by and between Bank and Borrower (the “Old Agreement”).

AutoNDA by SimpleDocs
OPEN MARKET SALE AGREEMENTSM
Market Sale • December 30th, 2021 • Cytosorbents Corp • Surgical & medical instruments & apparatus • New York
COMPANY INC. SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • January 28th, 2014 • Cytosorbents Corp • Surgical & medical instruments & apparatus • New York

This Securities Purchase Agreement (“Agreement”) is made as of Date __, 2014, by and between Company Inc., a STATE corporation (the “Company”), and each of the purchasers who execute the Purchaser Signature Page hereto (the “Purchaser”).

Executive Employment Agreement
Employment Agreement • May 30th, 2017 • Cytosorbents Corp • Surgical & medical instruments & apparatus • New Jersey

This Executive Employment Agreement (the “Employment Agreement”) by and between Eric R. Mortensen (the “Executive”) and CytoSorbents Medical, Inc. (with its parent CytoSorbents Corporate, hereinafter referred to as the “Company”), effective as of June 1, 2017.

EMPLOYMENT AGREEMENT
Employment Agreement • July 1st, 2008 • MedaSorb Technologies CORP • Surgical & medical instruments & apparatus • New Jersey

THIS EMPLOYMENT AGREEMENT (this "Agreement") is entered into this 18th day of June, 2008, by and between MedaSorb Technologies Corporation, (the "Company"), and Al Kraus ("Employee"). This Employment agreement is contingent upon closing a $4 million Series B financing led by NJTC Venture Fund (“NJTC”) in June 2008 and will replace the employment agreement executed between Employee and the Company dated December 31, 2007. If this condition is not met, there will be no change in the Employee’s current employment agreement.

Success Fee Letter CytoSorbents Corporation
Cytosorbents Corp • April 4th, 2018 • Surgical & medical instruments & apparatus

Reference is herein made to that certain Amended and Restated Loan and Security Agreement (the “Loan Agreement”), dated as of even date herewith, by and between Western Alliance Bank, an Arizona corporation (“Bank”), and CytoSorbents Corporation, a Delaware corporation and CytoSorbents Medical, Inc., a Delaware corporation (individually and collectively, jointly and severally “Borrower”). CytoSorbents Corporation may be referred to herein as “Parent.” Capitalized terms used but not otherwise defined herein shall have the respective meanings given to them in the Loan Agreement. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by Borrower hereby agrees to pay to the Bank, an amount equal to 6.37% of the original aggregate amount of Term B Loans made under the Loan Agreement (“Success Fee”), promptly upon the occurrence of the first Liquidity Event (as defined herein) after the date hereof in accordance with the payment instructions that th

AGREEMENT AND CONSENT
Agreement and Consent • July 1st, 2008 • MedaSorb Technologies CORP • Surgical & medical instruments & apparatus • New York

This AGREEMENT AND CONSENT (this “Agreement”), dated as of June 25, 2008, is made by and among MedaSorb Technologies Corporation, a Nevada corporation (the “Company”), and the holders of the Series A 10% Cumulative Convertible Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”) of the Company signatory hereto (each a “Holder” and collectively the “Holders”).

Internet Kiosk Service Agreement
Internet Kiosk Service Agreement • September 8th, 2004 • Gilder Enterprises Inc • Services-computer programming, data processing, etc. • British Columbia

PAYKIOSKS INTERNET TERMINALS INC., a British Columbia corporation having its registered offices at 3545 West 3rd Avenue, British Columbia, Canada V6R 1L8

FORM CONVERTIBLE NOTE Maturity Date: 12 Months from Note closing date
Cytosorbents Corp • June 27th, 2013 • Surgical & medical instruments & apparatus

FOR VALUE RECEIVED, the undersigned CytoSorbents Corporation (the “Company”), promises to pay in equity as set forth below on or before June 21, 2014, to_________________________ (“Creditor"), at New York, NY the principal sum of ____________ ($0.00) (the “Principal”), together with interest accruing thereon at the rate of 8% per annum, payable on or before maturity of the Note. This Note together with any Warrants issued hereunder shall be defined as the Securities (the “Securities”).

OPTION AGREEMENT
Option Agreement • March 29th, 2004 • Gilder Enterprises Inc • British Columbia
Re: Salary Reduction Agreement
Cytosorbents Corp • April 3rd, 2024 • Surgical & medical instruments & apparatus

We are sending you this letter to memorialize your election to reduce your annual base salary by 15% to $[Amount] (your “Reduced Pay”), which represents a reduction in the amount of $[Amount] (“Reduction Amount”), effective for the period of April 1, 2024 through December 31, 2024 (the “Reduction Period”). Your base salary will be based on your Reduced Pay during the Reduction Period, which shall be paid in accordance with the Company’s payroll, subject to your continued employment with the Company. Following the Reduction Period, your Reduced Pay will be automatically reset to your base salary in effect prior to the Reduction Amount. This letter will serve to amend and modify the terms of any employment agreement you have with the Company, including any reference to base salary as set forth in such employment agreement.

MANAGEMENT AND ADMINISTRATIVE SERVICES AGREEMENT
Management and Administrative Services Agreement • June 9th, 2004 • Gilder Enterprises Inc • Services-computer programming, data processing, etc.
Contract
Confidential Treatment • March 7th, 2019 • Cytosorbents Corp • Surgical & medical instruments & apparatus

Confidential treatment has been requested with respect to portions of this agreement as indicated by “[***]” and such confidential portions have been deleted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Time is Money Join Law Insider Premium to draft better contracts faster.